PUBLISHER: Grand View Research | PRODUCT CODE: 2132467
PUBLISHER: Grand View Research | PRODUCT CODE: 2132467
The global pressure ulcer treatment market size was estimated at USD 6.1 billion in 2025 and is projected to grow from USD 6.4 billion in 2026 to USD 9.8 billion by 2033, at a CAGR of 6.2% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 42.5% in 2025. The growth of the global market for pressure ulcer treatments is driven by the rising prevalence of pressure ulcers among elderly and immobile populations, increasing hospital and long-term care needs, greater adoption of advanced wound-care technologies, and growing emphasis on pressure ulcer prevention and standardized wound assessment.
The continued burden of pressure injuries is driving demand for effective treatment and wound-care solutions across hospitals and other healthcare settings. According to the 2025 AHRQ Network of Patient Safety Databases Chartbook, 93,807 pressure injury events were reported through December 2024. Among the 17,077 events with valid information on the most advanced stage, 66.6% (11,377 cases) were deep tissue pressure injuries, 10.2% (1,748 cases) were Stage 3, and approximately 21.1% (3,600 cases) were unstageable. The report also found that 77.1% of 17,936 reported events involved patients who had received a preventive intervention, indicating that pressure injuries continue to occur despite preventive measures. Furthermore, 63.8% of reported cases developed a secondary morbidity or had an unknown outcome, while Stage 4 injuries showed the highest reported harm rate at 82%. The substantial number of advanced and potentially harmful pressure injuries supports continued demand for advanced dressings, negative pressure wound therapy, pressure-relieving systems, and other treatment solutions.
In addition, the growing burden of pressure ulcers is driving demand for effective prevention, diagnosis, and treatment solutions, particularly among high-risk patients such as those with spinal cord injuries and limited mobility. The Spinal Injuries Association's Stop the Pressure Day 2025 highlighted the continuing impact of pressure ulcers in the UK. According to the initiative, more than 700,000 people are affected by pressure ulcers in the UK, with around 180,000 new cases diagnosed each year. The average treatment cost was reported at £11,703.54 per pressure ulcer per day (approximately USD 15,600), resulting in an estimated £22.4 million per day (approximately USD 29.9 million) in costs to the NHS. The initiative also highlighted gaps in care: among 761 people with spinal cord injuries surveyed in 2025, nearly 1 in 5 experienced a pressure ulcer during the previous year, while almost one-quarter reported that their pressure ulcer was not correctly diagnosed or treated. These findings highlight the substantial clinical and economic burden and support continued demand for pressure ulcer treatment and prevention solutions.
Manufacturers offer a diverse portfolio of pressure ulcer management products to address different levels of patient risk and wound severity. For instance, Novacare offers solutions such as dynamic mattress systems, hybrid mattresses, and advanced pressure - redistribution surfaces. Its portfolio includes ASX, ASX digital 6-inch, Smartline Hybrid, Smartline Pro, and APM 440 XC, designed for pressure ulcer prevention and management across diverse clinical needs.
Clinical trials landscape:
Clinical trials are supporting innovation in the market by generating evidence on the safety and effectiveness of advanced therapies for severe and difficult-to-treat wounds. Research is focused on treatments that can address infection, improve wound healing, reduce recurrence, and limit the need for systemic antibiotics. For instance, in February 2024, Biocomposites announced the launch of the Phase II BLADE-OPU2 clinical trial in the U.S. to evaluate the safety and efficacy of STIMULAN VG, a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin, for the treatment of Stage IV pressure ulcers. The company reported that approximately 200,000 Stage IV pressure ulcer cases occur annually in the U.S. The trial is intended to evaluate whether localized antibiotic delivery can improve patient outcomes and reduce recurrent infections, highlighting the increasing development of advanced therapies for severe pressure ulcers.
Global Pressure Ulcer Treatment Market Report Segmentation
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pressure ulcer treatment market report based on product, clinical severity, end use, and region: